Lantern Pharma IncNASDAQ:LTRN
- LAST PRICE3.1400
- TODAY'S CHANGE (%)0.0100 (0.3195%)
- Bid / Lots3.1000/ 8
- Ask / Lots3.2500/ 19
- Open / Previous Close3.0900 / 3.1300
- Day Range
- 52 Week Range
- Volume22,825
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LTRN |
|---|---|---|
| 09:32 ET | 624 | 3.09 |
| 09:51 ET | 1149 | 3.17 |
| 09:57 ET | 100 | 3.15 |
| 10:02 ET | 635 | 3.175 |
| 10:18 ET | 350 | 3.16 |
| 10:20 ET | 340 | 3.12 |
| 10:36 ET | 1049 | 3.14 |
Today
Nov 19, 2024
Nov 7, 2024
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board, from 8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lantern Pharma Inc | 33.2M | -1.8x | --- |
Grace Therapeutics, Inc | 33.3M | -3.1x | --- |
NextCure Inc | 33.3M | -0.6x | --- |
Estrella Immunopharma Inc | 32.9M | -4.4x | --- |
ProMIS Neurosciences Inc | 33.7M | -5.0x | --- |
CERo Therapeutics Holdings Inc | 32.2M | -0.4x | --- |
Company Information
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Contact Information
- Headquarters
- 1920 MCKINNEY AVENUE, 7TH FLOORDALLAS, TX, United States 75201
- Phone
- 972-277-1136
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Donald Keyser
- President, Chief Executive Officer, Director
- Panna Sharma
- Chief Financial Officer, Secretary
- David Margrave
- Chief Scientific Officer
- Kishor Bhatia
- Chief Medical Officer
- Marc Chamberlain
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $33.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-1.77 |
Book Value | $3.82 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
